Betta Pharmaceuticals shares hit the down limit after EyePoint Pharmaceuticals’
US-listed stock plunged ~67% overnight following a Phase III failure of fulonib
in wAMD; Betta holds Greater China rights to the candidate.
2026-08-18
Betta Pharmaceuticals shares hit the down limit after EyePoint Pharmaceuticals’
US-listed stock plunged ~67% overnight following a Phase III failure of fulonib
in wAMD; Betta holds Greater China rights to the candidate.
